Abstract | PURPOSE: METHODS: RESULTS: Intravitreal administration of bevacizumab led to a several-fold increase of RANTES, MCP-1, and IFN-γ concentrations in aqueous humor of endotoxin-treated rats. CONCLUSIONS: Given the exacerbating effect of bevacizumab on inflammation agents and considering the increasing use of bevacizumab as an off-label intravitreal agent, care should be taken if an underlying inflammatory disease is present.
|
Authors | Siv Johnsen-Soriano, Emma Arnal, María Sancho-Tello, María Muriach, Inmaculada Almansa, Francisco Bosch-Morell, Amparo Navea, Francisco J Romero |
Journal | European journal of ophthalmology
(Eur J Ophthalmol)
2011 Jul-Aug
Vol. 21
Issue 4
Pg. 427-33
ISSN: 1724-6016 [Electronic] United States |
PMID | 21038308
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Ccl2 protein, rat
- Chemokine CCL2
- Chemokine CCL5
- Cytokines
- Lipopolysaccharides
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Interferon-gamma
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage)
- Animals
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Aqueous Humor
(metabolism)
- Bevacizumab
- Chemokine CCL2
(metabolism)
- Chemokine CCL5
(metabolism)
- Cytokines
(metabolism)
- Disease Models, Animal
- Enzyme-Linked Immunosorbent Assay
- Interferon-gamma
(metabolism)
- Intravitreal Injections
- Lipopolysaccharides
- Male
- Rats
- Rats, Inbred Lew
- Uveitis
(chemically induced, drug therapy, metabolism)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|